Evidence map›Paper›PMID 28658622›Full record

ArticleCell reports2017

Lanosterol Modulates TLR4-Mediated Innate Immune Responses in Macrophages.

Elisa Araldi, Marta Fernández-Fuertes, Alberto Canfrán-Duque, Wenwen Tang, Gary W Cline, Julio Madrigal-Matute, Jordan S Pober, Miguel A Lasunción, Dianqing Wu, Carlos Fernández-Hernando and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Deciphering the immunomodulatory mechanisms ofFrontiers in cell and developmental biology · 2025
    Article
  14. Review
  15. Article
  16. Reprogramming of the LXRα Transcriptome Sustains Macrophage Secondary Inflammatory Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  17. Natural Products Biosynthesis byAntibiotics (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Elisa AraldiDepartment of Comparative Medicine, Department of Pathology, Program in Integrative Cell Signaling and Neurobiology of Metabolism and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Departments of Medicine and Cell Biology, Leon H. Charney Division of Cardiology and Cell Biology, New York University School of Medicine, New York, NY 10016, USA.
Marta Fernández-FuertesDepartment of Comparative Medicine, Department of Pathology, Program in Integrative Cell Signaling and Neurobiology of Metabolism and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.
Alberto Canfrán-DuqueDepartment of Comparative Medicine, Department of Pathology, Program in Integrative Cell Signaling and Neurobiology of Metabolism and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA; Servicio de Bioquímica-Investigación, Hospital Universitario Ramón y Cajal, IRyCIS, Madrid y CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), ISCIII, 28029 Madrid, Spain.
Wenwen TangDepartment of Pharmacology and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.
Gary W ClineDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Julio Madrigal-MatuteDepartments of Medicine and Cell Biology, Leon H. Charney Division of Cardiology and Cell Biology, New York University School of Medicine, New York, NY 10016, USA.
Jordan S PoberDepartment of Immunobiology and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.
Miguel A LasunciónServicio de Bioquímica-Investigación, Hospital Universitario Ramón y Cajal, IRyCIS, Madrid y CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), ISCIII, 28029 Madrid, Spain.
Dianqing WuDepartment of Pharmacology and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA.
Carlos Fernández-HernandoDepartment of Comparative Medicine, Department of Pathology, Program in Integrative Cell Signaling and Neurobiology of Metabolism and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: carlos.fernandez@yale.edu.
Yajaira SuárezDepartment of Comparative Medicine, Department of Pathology, Program in Integrative Cell Signaling and Neurobiology of Metabolism and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: yajaira.suarez@yale.edu.
Yale University · USNew York University · USHospital Universitario Ramón y Cajal · ES

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0M
Yale Rheumatic Diseases Research Core CenterP30AR053495 · NIAMS · YALE UNIVERSITY · PI SHLOMCHIK, WARREN D · 2007 to 2017
$7.0M
Signaling mechanisms and functions related to patho-physiology of vascular, lung and blood systemsR35HL135805 · NHLBI · YALE UNIVERSITY · PI WU, DIANQING · 2017 to 2023
$6.4M
Novel insights into the molecular and cellular mechanism regulating lipid metabolism and atherosclerosisR35HL135820 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2017 to 2023
$6.0M
microRNAs in vascular diseasesR01HL105945 · NHLBI · YALE UNIVERSITY · PI SUAREZ, YAJAIRA · 2011 to 2020
$3.7M
Caveolin-1 in Lipoprotein Metabolism and Atherosclerosis.R01HL106063 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2011 to 2016
$2.5M
Role of microRNAs in lipid metabolism and cardiovascular diseaseR01HL107953 · NHLBI · YALE UNIVERSITY · PI FERNANDEZ HERNANDO, CARLOS · 2011 to 2016
$2.4M
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NHLBI NIH HHS R01 HL105945NHLBI NIH HHS R01 HL106063NHLBI NIH HHS R01 HL107953NHLBI NIH HHS R35 HL135805NHLBI NIH HHS R35 HL135820NIAMS NIH HHS P30 AR053495
6 · The paper itself

Abstract

Macrophages perform critical functions in both innate immunity and cholesterol metabolism. Here, we report that activation of Toll-like receptor 4 (TLR4) in macrophages causes lanosterol, the first sterol intermediate in the cholesterol biosynthetic pathway, to accumulate. This effect is due to type I interferon (IFN)-dependent histone deacetylase 1 (HDAC1) transcriptional repression of lanosterol-14α-demethylase, the gene product of Cyp51A1. Lanosterol accumulation in macrophages, because of either treatment with ketoconazole or induced conditional disruption of Cyp51A1 in mouse macrophages in vitro, decreases IFNβ-mediated signal transducer and activator of transcription (STAT)1-STAT2 activation and IFNβ-stimulated gene expression. These effects translate into increased survival to endotoxemic shock by reducing cytokine secretion. In addition, lanosterol accumulation increases membrane fluidity and ROS production, thus potentiating phagocytosis and the ability to kill bacteria. This improves resistance of mice to Listeria monocytogenes infection by increasing bacterial clearance in the spleen and liver. Overall, our data indicate that lanosterol is an endogenous selective regulator of macrophage immunity.

Indexed as

AnimalsDown-RegulationFemaleGene Knockout TechniquesHumansImmunity, InnateLanosterolMacrophagesMiceMice, Inbred C57BLMice, TransgenicSterol 14-DemethylaseToll-Like Receptor 4CYP51A1 protein, humanLanosterolSterol 14-DemethylaseTLR4 protein, humanTlr4 protein, mouseToll-Like Receptor 4Cyp51A1innate immunitylanosterolmacrophageTLR4

Identifiers

PMID28658622
PMCPMC5553565
OpenAlexW2729880194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.